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The administration of human rabies postexposure pro-
phylaxis near Marseille (southern France) has changed 
since the eradication of terrestrial mammal rabies in 2001. 
Most injuries were associated with indigenous dogs; rabies 
vaccine was overprescribed. We suggest that the World 
Health Organization guidelines be adapted for countries 
free of terrestrial mammal rabies.
T
he last case of human rabies acquired in France was 
reported in 1924, and rabies was ofﬁ  cially declared 
eliminated in terrestrial mammals in 2001 (1). However, 
conﬁ  rmed rabid dogs from North Africa have been im-
ported into France (2,3), and indigenous bats have been 
regularly found to be infected by rabies-related viruses 
(4). Marseille is the main international seaport in southern 
France; it handles heavy daily maritime trafﬁ  c from North 
Africa, where numerous human cases are reported in rela-
tion with rabid dog bites. Management of patients exposed 
to these potentially rabid animals poses speciﬁ  c problems, 
and the decision to prescribe rabies vaccine and/or rabies 
immunoglobulin depends on the origin of the animal, as it 
does in the United Kingdom (5).
The Study
From 1994 through 2005, epidemiologic data on 
animal-related injuries and associated postexposure pro-
phylaxis (PEP) treatment were prospectively collected for 
Marseille Rabies Treatment Centre patients. Only patients 
who had been injured in France were selected; rabies PEP 
for travelers who were injured abroad is detailed elsewhere 
(6). Of the 4,965 eligible patients, 4,367 were outpatients 
or inpatients (192–488/year), and from 2001 through 2005, 
a total of 598 were managed by teleconsultation only be-
cause their exposure risk was considered to be zero.
The number of inpatients and outpatients decreased 
markedly from 1999 to 2001 (Figure 1), which is consistent 
with the general decrease in the number of PEP treatments 
in France after the elimination of terrestrial mammal rabies 
(7). Furthermore, prescreening of persons by telephone also 
contributed to this decrease. The increase observed during 
2004–2005 is likely an effect of the international alert in 
relation to the cases of rabid dogs imported from Morocco; 
these cases were intensively reported by the French media. 
The proportion of animal-related injuries tended to increase 
in late spring/early summer (Figure 2), probably as a result 
of increased outdoor activities in southern France, which 
makes contact with animals more likely.
The overall annual incidence of injured patients seek-
ing care for rabies PEP was 16/100,000, which is consis-
tent with incidence recently reported in United States (8,9) 
(where rabies is enzootic in bats and raccoons) but far less 
than that reported in recently available studies from the 
canine rabies–endemic countries of Turkey (467/100,000) 
(10) and India (1,700/100,000) (11). The overall mean an-
nual incidence in our study was 20/100,000 before 2001 
and 11/100,000 after 2001.
Dogs accounted for 81.2% of all injuries. By contrast, 
a recent study on pet demographics in France indicated 
that dog and cat populations are nearly similar at 8.51 mil-
lion and 9.94 million, respectively (12). This ﬁ  nding sug-
gests that dogs, more often than cats, are responsible for 
severe injuries that lead persons to seek care for rabies 
PEP. The mean annual incidence of animal-related inju-
ries was lower in rural than in urban communities (online 
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DISPATCHES
1452  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 9, September 2008
Author afﬁ  liations: Hôpital Nord, Assistance Publique– Hôpitaux de 
Marseille, Marseille, France (P. Gautret, G. Soula, M.-J. Soavi J. 
Delmont, P. Parola, P. Brouqui); Centre de Formation et Recherche 
en Médecine et Santé Tropicales, Marseille (G. Soula, J. Delmont); 
Institut Pasteur, Paris, France (Y. Rotivel); and Centre Hospitalier 
des Armées, Niamey, République du Niger (H. Adamou)
DOI: 10.3201/eid1409.071322
Figure 1. Number of injured patients per year seeking care for 
rabies postexposure prophylaxis, Marseille Centre, Marseille, 
France, 1994–2005.
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content/14/9/1452-Techapp.pdf). Because an estimation 
of the dog population in France indicated that 41% live 
in urban areas (12), our results suggest that a high human 
population density increases the probability of human–dog 
interactions and risk for injuries.
Among patients seeking care for rabies PEP, most 
were male (male:female ratio 1.49) and mean age was 31.5 
(median 29, range 0–96) years. Patients <15 years of age 
represented 26% of the cohort. The likelihood for animal-
related injuries among male patients was also dependant on 
the animal species involved; dogs, bats, and monkeys ac-
counted for most injuries (online Technical Appendix). In 
contrast, female patients were more likely to be injured by 
cats, a ﬁ  nding consistent with previous reports (13).
The mean time between injury and consultation was 2.6 
days (range 0–365 days) and did not statistically vary by sex 
or age group. Time was longer in patients who were injured 
by bats (p<10–6, online Technical Appendix), probably be-
cause most bat bites are nonpainful and considered benign 
by patients who ignore the risk for rabies after bat contact.
Most injured persons experienced severe contact with 
animals (95.1%), categorized by the World Health Organi-
zation (WHO) as category III (14). Most injuries were on 
the limbs (online Technical Appendix).
Animals were available for observation by a veterinar-
ian in 1,441 cases (33%). Rabies testing of animal is not 
available in southern France, and animals from this region 
should be sent to the Rabies Laboratory at the Pasteur In-
stitute in Paris, which was done for 89 cases, of which 20 
cases were related to a conﬁ  rmed rabid source from Africa 
or the Middle East (Table 1).
The proportion of patients who received treatment 
increased from 42% during 1994–2000 to 84.3% during 
2001–2005 (p<10–6) as a result of prescreening by telephone 
(Table 2). Since 2001, when the animal was not available 
for surveillance by a veterinarian (which includes numer-
ous cases in which the animal was available for observa-
tion by its owner), complete treatment was given to most 
(89%) patients. Rabies immunoglobulin was provided to 
3.2% of these patients, most of whom were injured by bats 
or severely injured by domestic animals when the owner 
was not identiﬁ  ed or when surveillance of the responsible 
animal was not possible. No cases of rabies infection were 
identiﬁ  ed in treated persons.
Conclusions
Our rabies PEP data are consistent with data from the na-
tional French Referral Center (7). The therapeutic approach 
in France is partly in accordance with WHO general recom-
mendations that in rabies-free areas where adequate rabies 
surveillance is in effect, rabies PEP may not be required, de-
pending on the outcome of a risk assessment conducted by a 
medical expert (14). Systematic rabies PEP is cost-effective 
and safe but should not be used if the biting animal is unlike-
ly to be rabid. Furthermore, treating a patient with only vac-
cine when the animal is under observation could reduce the 
beneﬁ  t of further administration of rabies immunoglobulin if 
the time between vaccination and rabies immunoglobulin in-
jection is >7 days (15). If the treatment cannot be delayed, it 
should include both vaccination and rabies immunoglobulin 
in cases of category III injury. From 2001 through 2005, not 
vaccinating the patient when the animal was under observa-
tion by its owner or a veterinarian would have represented an 
overall savings of 177,600 Euros.
To minimize overprescription of vaccination for rabies 
PEP when treatment may be unjustiﬁ  ed, we recommend 
delaying the initiation of rabies treatment in injuries involv-
ing an apparently healthy indigenous dog or cat that can 
be kept under veterinary or animal-owner observation for 
2 weeks, which is the maximum rabies incubation time in 
these animals. Doing so would result in no rabies treatment 
for almost all such patients. However, when animals are not 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 9, September 2008  1453 
Figure 2. Average proportions of injured patients seeking care 
for rabies postexposure prophylaxis, by month, Marseille Centre, 
Marseille, France, 1994–2005. 
Table 1. Characteristics of postexposure prophylaxis for patients exposed to confirmed rabies source, Marseille, France, 1994–2005 
Date of exposure No. treatments Confirmed source Location of exposure, France
1994 Jul  1 Fox Northeast
1995 Nov  14 Dog* Southeast
1998 May/Jun  2 Dog† Southeast
2004 Aug  3 Dog‡ Southwest 
*Imported from Burkina Faso. 
†Unknown origin; rabid strain close to Egyptian isolates. 
‡Imported from Morocco (187 treatments were given in France; most in Bordeaux Centre). available for observation, complete rabies PEP treatment 
should be initiated. Given the risk for importation of rabid 
animals from nearby rabies-endemic countries, immediate 
rabies PEP treatment according to WHO guidelines should 
be given when the following are involved: indigenous bats; 
animals illegally imported from rabies-endemic countries; 
or animals found in railway stations, trains, or other ports 
of entry. If the animal is suspected of being rabid at the 
time of exposure, conﬁ  rmatory testing should be conducted 
(online Technical Appendix). All travelers visiting coun-
tries where rabies is enzootic should be informed about the 
risks of bringing animals back to their home country and 
about the WHO recommendations regarding rabies vacci-
nation of imported animals (14).
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Table 2. Treatment for injured patients seeking care for rabies postexposure prophylaxis, by animal rabies status, Marseille, France,
1994–2005*
Animal status 
1994–2000, no. (%)  2001–2005, no. (%)  
Patient receipt of PEP*  Unknown† Rabid‡ Not rabid§ Unknown† Rabid‡ Not rabid§
Total 1,916 (61.5) 21 (0.6) 1,185 (37.9) 911 (73.2) 5 (0.4) 329 (26.4)
Unknown 0 0 0 4 (0.5) 0 0
None 761 (39.7) 1 (4.8) 1,048 (88.4) 34 (3.7) 0 158 (48.0)
Treatment completed 1,000 (52.2) 20 (95.2) 19 (1.6) 811 (89.0) 5 (100) 45 (13.7)
Treatment stopped 42 (2.2) 0 117 (9.9) 3 (0.3) 0 126 (38.3)
Lost to follow-up 113 (5.9) 0 1 (0.1) 59 (6.5) 0 0
RIG 2 (0.2) 20 (95.2) 1 (0.1) 29 (3.2) 0 14 (4.3)
*PEP, postexposure prophylaxis; RIG, rabies immunoglobulin (% as proportion of treatments including rabies PEP). 1994–2000, n = 3,122; 2001–2005,  
n = 1,245. 
†Animal not available for observation by a veterinarian (including cases where animal was available for observation by its owner).
‡Animal proven to be rabid by laboratory testing or considered rabid upon clinical criteria. 
§Animal proven to be not rabid by laboratory testing or after 2 weeks of observation by a veterinarian. 